Full Press Release Details
According to Dr. Azzi, "Kidney transplant providers currently have sub-optimal tools to care for transplant patients and need more reliable tools to ensure post-operative success of kidney transplants, particularly for those patients that are far from academic centers." He continued, "There is increased risk for non-compliance in patients after one year as most cannot continue check-ups due to logistical or resource constraints. Non-compliance after the first year can lead to subclinical rejections, kidney fibrosis, and mortality, as well as increased costs to the healthcare system. I expect the non-invasive urine-based ExoTRU test will be well-received among transplant care providers as patients can easily provide a urine sample from the comfort and convenience of their home, enabling improved allograft monitoring."
"ExoTRU is an important test to improve the management and care of kidney transplant patients," said Chuck Kummeth , President and Chief Executive Officer of Bio-Techne. "With ExoDx Prostate (EPI) already commercially available, ExoTRU will be the second innovative liquid biopsy test launched by the Exosome Diagnostics team. We look forward to continued development and commercilization of our rich pipeline of diagnostic tests leveraging the power of exosomes."
See press release from Brigham and Women's Hospital here .
About Bio-Techne Corporation (NASDAQ: TECH )
Contact: David Clair , Senior Director, Investor Relations & Corporate Development [email protected] 612-656-4416
SOURCE Bio-Techne Corporation